Floatz logo

Modified Vaccinia Virus Ankara Vaccine Expressing P53

Recurrent Ovarian Epithelial Cancer

City of Hope Medical CentervaccinePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

244 Active assets in the Recurrent Ovarian Epithelial Cancer cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Carboplatin
University of Washington
Phase 3BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Modified Vaccinia Virus Ankara Vaccine Expressing P53 is also rated in:

primary peritoneal carcinomaDormant
B
Indicative ·
60 / 100
View asset →
fallopian tube carcinomaDormant
B
Indicative ·
58 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →